Compliance of osteoporotic patients with different treatment regimens.
Explore this paper's citation graph
Summary
At least 20% of the patients discontinued chronic treatment for osteoporosis during the initial 6 months of therapy, and the main reasons were gastrointestinal side effects in the alendronate group and fear of side effects and high drug price in the raloxifene group.
- Type
- article
- Published
- 2003-12-01
- Cited by
- 102
- References
- 18
- OpenAlex
- https://openalex.org/W123345555
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:16112312
Keywords
Medicine, Raloxifene, Osteoporosis, Bisphosphonate, Internal medicine
References
- Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement Therapy
- Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
- Osteoporosis: new hope for the future.
- Compliance Considerations with Hormone Replacement Therapy
- Postmenopausal osteoporosis
- [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
- Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing.
- Bisphosphonates: from the laboratory to the clinic and back again.
- Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen
- Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.
- Pharmacokinetics of raloxifene and its clinical application.
- The meaning of medications: another look at compliance.
- Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis.
- Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis.
Cited by
- Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates.
- The in vitro and in vivo effects of the low molecular weight fucoidan on the bone osteogenic differentiation properties
- Patient Safety and Quality: An Evidence-Based Handbook for Nurses
- The diagnosis and treatment of primary osteoporosis according to current guidelines.
- Frequency of and reasons for medication non‐fulfillment and non‐persistence among American adults with chronic disease in 2008
- Prescribing of bisphosphonates and antibiotics in Pakistan: challenges and opportunities for the future
- Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
- Medication Management of the Community-Dwelling Older Adult
- Quelles sont les options pharmacologiques envisageables pour un patient inobservant à son traitement au bisphosphonate oral
- Histomorphometric and histological evaluations of the simvastatin effect on alveolar bone loss induced by cyclosporine A in rats
- Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
- Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture
- Condicionantes de la efectividad de un tratamiento farmacológico en la osteoporosis. Adherencia y cumplimiento
- Non-compliance: the Achilles' heel of anti-fracture efficacy
- Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
- Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
- Osteoporosis medication profile preference: results from the PREFER‐US study
- Determinants of adherence to osteoporosis treatment in clinical practice
- A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis
- Medication persistence with weekly versus daily doses of orally administered bisphosphonates.
Related papers
- Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
- Antiresorptive agents, raloxifene, and PHARMAC.
- Pharmacological Management of Severe Postmenopausal Osteoporosis
- Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene
- Alendronate
- Preventing Fractures in Postmenopausal Women with Osteoporosis
- Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.
- A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.